Comparative Efficacy of 5-Hydroxytryptophan Delivered via Capsule or Functional Food Bar on Mood, Sleep, and Salivary Cortisol: A Randomised, Double-Blind, Placebo-Controlled Trial
Journal of Food Science and Nutrition Therapy · 2026 · 12 (1) · 1-8
DOI: 10.17352/jfsnt.000059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Food Science and Nutrition Therapy, 2026. Verfasst von Rachel Nye Venter und 4 weiteren Autor:innen. Die Arbeit nennt 30 Literaturangaben.
Abstract (Originalsprache)
Objective
Poor sleep quality and elevated psychological distress are highly prevalent in young adults. This randomised, double-blind, placebo-controlled, four-arm parallel group clinical trial evaluated the comparative efficacy of 5-hydroxytryptophan (5-HTP) derived from organic Griffonia simplicifolia delivered via a traditional capsule versus a functional food snack bar on mood, sleep quality, and physiological stress markers.
Methods
Eighty healthy adults aged 18-40 years with self-reported poor sleep quality and low mood were randomised in a 1:1:1:1 ratio to receive a Placebo Capsule, Placebo Bar, 5-HTP Capsule (150 mg/day), or 5-HTP Bar (150 mg/day) for 25 days. Outcomes included the Depression Anxiety Stress Scales-21 (DASS-21), the Pittsburgh Sleep Quality Index (PSQI), and salivary cortisol. Participants and all study personnel involved in conducting or evaluating the trial remained unaware of the treatment assignments. Efficacy was evaluated using an Intention-to-Treat (ITT) framework, with Last Observation Carried Forward (LOCF) used for missing follow-up data and ANCOVA models used to adjust for baseline values.
Results
Both active 5-HTP groups demonstrated improvements in DASS-21, PSQI, and salivary cortisol outcomes by Day 25. Placebo groups showed smaller mean changes from baseline: DASS-21 decreased by 2.35 points in PLA-CAP and 1.75 points in PLA-BAR, PSQI decreased by 1.60 points in each placebo group, and morning and evening cortisol changed by no more than 0.11 and 0.08 µg/dL, respectively. Baseline-adjusted ANCOVA models showed a significant overall treatment group effect. Supportive pairwise comparisons of the unadjusted Day 25 scores showed significant differences between each active 5-HTP group and its format-matched placebo group (p < 0.001). No statistically significant differences in clinical response were observed between the active capsule and functional food bar delivery formats for DASS-21 or PSQI outcomes.
Conclusions
Daily supplementation with 150 mg/day of 5-HTP is associated with significant improvement in mood and sleep quality in young adults, with supportive reductions in salivary cortisol. Under the conditions of this study, the functional food bar produced an observed clinical response comparable to the traditional capsule format. Trial registered with the Clinical Trials Registry-India (CTRI/2024/02/063100).
Zitieren
APA
Venter, R. N., Wildman, R. E., Haub, M., Riddell, M. K., & Chandradhara, D. (2026). Comparative Efficacy of 5-Hydroxytryptophan Delivered via Capsule or Functional Food Bar on Mood, Sleep, and Salivary Cortisol: A Randomised, Double-Blind, Placebo-Controlled Trial. Journal of Food Science and Nutrition Therapy, 12(1), 1-8. https://doi.org/10.17352/jfsnt.000059
Vancouver
Venter RN, Wildman RE, Haub M, Riddell MK, Chandradhara D. Comparative Efficacy of 5-Hydroxytryptophan Delivered via Capsule or Functional Food Bar on Mood, Sleep, and Salivary Cortisol: A Randomised, Double-Blind, Placebo-Controlled Trial. Journal of Food Science and Nutrition Therapy. 2026;12(1):1-8. doi:10.17352/jfsnt.000059
BibTeX
@article{Venter2026,
author = {Venter, Rachel Nye and Wildman, Robert EC and Haub, Mark and Riddell, Melissa Kirby and Chandradhara, Divya},
title = {Comparative Efficacy of 5-Hydroxytryptophan Delivered via Capsule or Functional Food Bar on Mood, Sleep, and Salivary Cortisol: A Randomised, Double-Blind, Placebo-Controlled Trial},
journal = {Journal of Food Science and Nutrition Therapy},
year = {2026},
volume = {12},
number = {1},
pages = {1--8},
doi = {10.17352/jfsnt.000059}
}
EUVIMED